2024-04-25T15:52:36-05:00 2023-12-31 390974031 WEGNER CPAS LLP 419 N LEE ST ALEXANDRIA VA 223142301 990 2023-01-01 821199380 GLOBAL COALITION FOR ADAPTIVE RESEARCH INC GLOB 4154948020 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391754 RACHAEL COLEMAN CFO/COO 4154948020 2024-04-24 1 RACHAEL COLEMAN 999009999 0 GLENN MILLER CPA P00086726 7035190990 2024-04-24 2 AAL1 IAL1 2023 2023-04-26 12:10:37Z MEREDITH BUXTON 700 LARKSPUR LANDING CIRCLE 199 LARKSPUR CA 949391754 28779160 0 X GCARESEARCH.ORG X 2017 MD TO LEAD THE DEVELOPMENT AND ONGOING MANAGEMENT OF CLINICAL TRIAL PLATFORMS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF CURES FOR PATIENTS WITH RARE AND DEADLY DISEASES. 8 5 36 5 0 0 543271 3081228 34345933 23964880 483944 1733052 0 0 35373148 28779160 0 1158000 0 0 4724320 6144027 0 0 0 19359003 22408600 24083323 29710627 11289825 -931467 59575227 59610730 21752254 19617460 37822973 39993270 X OUR MISSION IS TO LEAD THE DEVELOPMENT AND ONGOING MANAGEMENT OF CLINICAL TRIAL PLATFORMS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF CURES FOR PATIENTS WITH RARE AND DEADLY DISEASES. 0 0 25455461 1008000 23845952 GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT (GBM AGILE), GCAR'S INITIAL AND MOST ADVANCED INITIATIVE, IS A GLOBAL PHASE 2/3 ADAPTIVE PLATFORM TRIAL, DESIGNED TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR GLIOBLASTOMA OVER TIME IN AN EFFORT TO IMPROVE PATIENT OUTCOMES. GBM AGILE HAS BEEN OPEN AND ENROLLING PATIENTS SINCE JULY 2019 WITH OVER 1,900 PATIENTS SCREENED TO DATE. IN 2023, SEVERAL PUBLICATIONS /PRESENTATIONS WERE CONDUCTED TO PRESENT DATA AND LATEST PROGRESS TO THE RESEARCH COMMUNITY, INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY, AND THE SOCIETY FOR NEURO-ONCOLOGY. ADDITIONALLY, GCAR PROVIDES ON-GOING SUPPORT TO THE GBM RESEARCH AND CLINICAL COMMUNITY THROUGH PHILANTHROPIC DONATIONS TO ADVOCACY GROUPS, AS WELL AS EDUCATION, OUTREACH AND CLINICAL COMMUNITY ENGAGEMENT. TO PROMOTE BRAIN CANCER AWARENESS IN 2023, GCAR PARTICIPATED IN ADVOCACY PARTNER FUND RAISING EVENTS, PANEL DISCUSSIONS, AND ACADEMIC CONFERENCES. NOTABLE HIGHLIGHTS INCLUDED RINGING THE NASDAQ CLOSING BELL ALONGSIDE PATIENTS, ADVOCACY PARTNERS, AND PHARMACEUTICAL PARTNERS TO PROMOTE BRAIN TUMOR AWARENESS MONTH AND PARTICIPATING IN THE WHITE HOUSE CANCER MOONSHOT FORUM ON BRAIN CANCER. 1497730 150000 118928 PROGRAMS IN DEVELOPMENT. ADDITIONAL EFFORTS ARE FOCUSED ON ACTIVITIES TO SUPPORT THE LAUNCH, DESIGN, EDUCATION, OUTREACH, AND CLINICAL COMMUNITY ENGAGEMENT FOR MULTIPLE PROGRAMS IN DEVELOPMENT INCLUDING BILIARY TRACT CANCER, OVARIAN CANCER, NEUROFIBROMATOSIS, AND PANCREATIC CANCER, ALL RARE AND DEADLY DISEASES WITH CRITICAL NEED FOR FURTHER DEVELOPMENT OF NEW TREATMENT OPTIONS FOR PATIENTS.1 SMALLER FEDERAL PROGRAM TO SUPPORT COVID RESEARCH WAS IN WIND-DOWN STAGE IN 2023 (ENDED FEBRUARY 2024). 160485 0 0 REMAP-COVID, A SUB-STUDY OF REMAP-CAP (A RANDOMIZED, EMBEDDED, MULTIFACTORIAL, ADAPTIVE PLATFORM TRIAL FOR COMMUNITY-ACQUIRED PNEUMONIA), WAS DEVELOPED TO TEST MULTIPLE INTERVENTIONS FOR THE TREATMENT OF PATIENTS HOSPITALIZED WITH COVID-19. GCAR SPONSORED REMAP-COVID IN THE US, WITH THE UNIVERSITY OF PITTSBURGH AS THE US REGIONAL COORDINATING CENTER. PARTNERING WITH ACADEMIA, INDUSTRY AND MULTIPLE HEALTHCARE SYSTEMS, OVER 500 PATIENTS WERE RANDOMIZED WITHIN FOUR DOMAINS IN THE US. WITH THE PANDEMIC WINDING DOWN, THE TRIAL WAS CLOSED IN JUNE 2023. IN 2023, 2 CLINICAL STUDY REPORTS WERE SUBMITTED TO THE AGENCY AND 4 KEY PUBLICATIONS WERE PRESENTED VIA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, NEW ENGLAND JOURNAL OF MEDICINE, AND INTENSIVE CARE MEDICINE. 27113676 1 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 22 0 36 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 5 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X RACHAEL COLEMAN 6172996471 700 LARKSPUR LANDING CIRCLE STE 199 LARKSPUR CA 949391754 SUJUAN BA PHD DIRECTOR 2.00 X 0 0 0 BRIAN ALEXANDER MD MPH DIRECTOR 2.00 X 0 0 0 FARAMARZ YOUSEFZADEH JD LLM CHAIRMAN OF THE BOARD 5.00 X 0 0 0 GARY GORDON MD PHD SENIOR MEDICAL ADVISOR AND DIRECTOR 16.00 X 180000 0 0 JOHN FRISHKOPF MMS DIRECTOR 2.00 X 0 0 0 TIMOTHY CLOUGHESY MD CHIEF MEDICAL OFFICER AND DIRECTOR 16.00 X X 180000 0 0 WK ALFRED YUNG MD INVESTIGATOR INTERNATIONAL CHAIR & DIRECTOR 2.00 X 25452 0 0 WEBSTER CAVENEE PHD DIRECTOR 2.00 X 0 0 0 MATTHEW VIVA DIRECTOR, LEGAL/SECRETARY 40.00 X 233092 0 23710 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER/PRESIDENT 40.00 X 840000 0 58687 RACHAEL COLEMAN CFO/COO/TREASURER 40.00 X 423673 0 25276 ASHLEY POWELL VICE PRESIDENT, TRIAL OPERATIONS 40.00 X 323287 0 33890 ROBERT MURRAY CHIEF BUSINESS OFFICER 40.00 X 434298 0 12042 RACHEL ROSENSTEIN SISSON SR DIR, COMMUNICATIONS/LEARNING & DEV 40.00 X 185366 0 18269 SARAH UNTCH DIRECTOR, TRIAL OPERATIONS 40.00 X 203953 0 25962 TRACEY ROBERTS DIRECTOR, TRIAL OPERATIONS 40.00 X 206600 0 24666 ADAM JOHNSON ASSOC DIR, CLINICAL DATA MANAGEMENT 40.00 X 166146 0 31960 JESSA DEMAS SR. MGR, STRATEGIC INITIATIVES 40.00 X 146250 0 5046 3548117 0 259508 16 0 1 0 IQVIA 1700 PERIMETER PARK DR MORRISVILLE NC 27560 CLINICAL RESEARCH 20504461 MEDIDATA 350 HUDSON ST 9TH FLOOR NEW YORK NY 10014 CLINICAL RESEARCH 346882 MEDQIA 10850 WILSHIRE BLVD STE 1170 LOS ANGELES CA 90024 CLINICAL RESEARCH 218115 WILSON SONSINI GOODRICH & ROSATI 650 PAGE MILL RD PALO ALTO CA 94304 LEGAL SERVICES 159964 BERRY CONSULTING LLC 3345 BEE CAVES RD STE 201 AUSTIN TX 78746 STATISTICAL CONSULTATION 130705 5 3081228 3081228 TRIAL REVENUE 541700 23964880 23964880 23964880 1733052 1733052 28779160 23964880 0 1733052 X 1152500 1152500 5500 5500 2793407 1885649 907758 2717893 1853375 864518 48053 32437 15616 302420 204144 98276 282254 190532 91722 165468 154508 10960 37890 37890 61318 61318 21478344 21441600 36744 16694 958 15736 36287 2744 33543 119838 6877 112961 15794 906 14888 251271 119616 131655 69027 29130 39897 156669 33200 123469 29710627 27113676 2596951 0 7218662 3206238 0 1546512 0 1079637 3062438 2040738 2146734 2848349 26178251 40029401 20969142 8859855 59575227 59610730 7592023 6428918 12660231 11938542 1500000 1250000 21752254 19617460 X 37822973 39993270 37822973 39993270 59575227 59610730 -931467 3101764 0 X 0 1 X 1 0 X 662857 365772 504130 543271 3081228 5157258 662857 365772 504130 543271 3081228 5157258 2416254 2741004 2303 5866 5504 483944 1733052 2230669 7387927 123262304 0.37100 0.77480 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 MONEY MARKET FUNDS 8859855 F 8859855 REFUNDABLE ADVANCE 1250000 1250000 31976188 3101764 156582 -61318 3197028 28779160 0 28779160 29805891 156582 156582 29649309 61318 61318 29710627 PART XI, LINE 2D - OTHER ADJUSTMENTS: INVESTMENT FEES -61,318. 1 0 0 0 0 0 0 0 0 0 EAST ASIA AND THE PACIFIC CLINICAL TRIAL SUPPORT 5500 WIRE TRANSFER 0 1 0 0 0 0 0 0 0 PART I, LINE 3: THE ORGANIZATION ACCOUNTS FOR EXPENDITURES IN THE LISTED REGIONS USING THE ACCRUAL METHOD OF ACCOUNTING. 1 CHOLANGIOCARCINOMA FOUNDATION 5526 WEST 13400 SOUTH STE 510 SALT LAKE CITY UT 84096 205776861 501(C)(3) 150000 0 CLINICAL TRIAL SUPPORT NATIONAL FOUNDATION FOR CANCER RESEARCH 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 042531031 501(C)(3) 500000 0 CLINICAL TRIAL SUPPORT AIM-HI ACCELERATOR FUND INC 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 824322538 501(C)(3) 500000 0 CLINICAL TRIAL SUPPORT 3 0 PART I, LINE 2: THE GRANTS WE ISSUED WERE UNRESTRICTED AND ARE INTENDED TO HELP SUPPORT THE RESPECTIVE ORGANIZATION'S MISSION. WE HAVE ASKED EACH ORGANIZATION TO KEEP ALL RECORDS OF THE USE OF THE GIFT IN THE NORMAL COURSE AND PROVIDE COPIES UPON REQUEST. X X 0 0 0 0 0 0 0 0 0 MEREDITH BUXTON CHIEF EXECUTIVE OFFICER/PRESIDENT 540000 0 300000 0 0 0 14400 0 44287 0 898687 0 0 0 RACHAEL COLEMAN CFO/COO/TREASURER 313673 0 110000 0 0 0 12540 0 12736 0 448949 0 0 0 ROBERT MURRAY CHIEF BUSINESS OFFICER 274298 0 160000 0 0 0 10542 0 1500 0 446340 0 0 0 ASHLEY POWELL VICE PRESIDENT, TRIAL OPERATIONS 223287 0 100000 0 0 0 22561 0 11329 0 357177 0 0 0 MATTHEW VIVA DIRECTOR, LEGAL/SECRETARY 181745 0 51347 0 0 0 7469 0 16241 0 256802 0 0 0 TRACEY ROBERTS DIRECTOR, TRIAL OPERATIONS 168000 0 38600 0 0 0 6720 0 17946 0 231266 0 0 0 SARAH UNTCH DIRECTOR, TRIAL OPERATIONS 164713 0 39240 0 0 0 6848 0 19114 0 229915 0 0 0 RACHEL ROSENSTEIN SISSON SR DIR, COMMUNICATIONS/LEARNING & DE 157803 0 27563 0 0 0 6300 0 11969 0 203635 0 0 0 ADAM JOHNSON ASSOC DIR, CLINICAL DATA MANAGEMENT 130771 0 35375 0 0 0 5800 0 26160 0 198106 0 0 0 GARY GORDON MD PHD SENIOR MEDICAL ADVISOR AND DIRECTOR 180000 0 0 0 0 0 0 0 0 0 180000 0 0 0 TIMOTHY CLOUGHESY MD CHIEF MEDICAL OFFICER AND DIRECTOR 180000 0 0 0 0 0 0 0 0 0 180000 0 0 0 JESSA DEMAS SR. MGR, STRATEGIC INITIATIVES 130000 0 16250 0 0 0 3846 0 1200 0 151296 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B CFO WILL REVIEW WITH ACCOUNTING FIRM. ONCE NEAR FINAL WILL REVIEW WITH CEO. WHEN FORM IS FINAL, FORM IS REVIEWED WITH THE ENTIRE BOARD. FORM 990, PART VI, SECTION B, LINE 12C EACH DIRECTOR AND OFFICER IS REQUIRED TO SUBMIT AN UPDATED CONFLICT OF INTEREST STATEMENT ON AN ANNUAL BASIS. TO THE EXTENT THAT RELATIONSHIPS ARE IDENTIFIED VIA THESE STATEMENTS AND OTHER INFORMATION, THE INDIVIDUAL'S CONSTITUENT RECORD IN THE COMPANY DATABASE IS UPDATED TO INCLUDE THIS INFORMATION, FACILITATING PERIODIC QUERIES, AS NECESSARY. ANY BOARD MEMBER WITH A CONFLICT MUST IDENTIFY THE CONFLICT AT ANY BOARD MEETING WHERE THE CONFLICT IS RELEVANT. THE MEMBER CANNOT BE PRESENT AT ANY PART OF THE MEETING WHERE THE RELEVANT TOPIC IS DISCUSSED OR VOTED ON. THE MEMBER CANNOT BE COUNTED FOR A QUORUM. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE AND BOARD OF DIRECTORS ARE RESPONSIBLE FOR THE REVIEW AND APPROVAL OF TOP LEVEL EXECUTIVE MANAGEMENT COMPENSATION ANNUALLY. INDEPENDENT PROFESSIONAL EXPERTS ARE CALLED UPON FOR HIGHER LEVEL POSITIONS AND ASSIST IN ESTABLISHING EXECUTIVE SALARIES IN THE COMPETITIVE MARKETPLACE. SALARIES IN BOTH FOR PROFIT AND NOT FOR PROFIT ORGANIZATIONS ARE EVALUATED WITH THE INTENT ON ENSURING THAT THE EXECUTIVE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. THE REVIEW INCLUDES INCENTIVE PLANS AND ALL FRINGE BENEFITS AS WELL AS BASE SALARY ARRANGEMENTS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G TRIAL EXPENSES: PROGRAM SERVICE EXPENSES 21,441,600. MANAGEMENT AND GENERAL EXPENSES 18,432. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 21,460,032. 401K MANAGEMENT: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 2,812. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,812. G&A CONSULTING FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 15,500. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 15,500.